Chronic Paediatric Conditions — MCQs
On this page
A 6-year-old boy with epilepsy controlled on lamotrigine presents with a 2-day history of fever, malaise, and a widespread erythematous rash. On examination, he has a maculopapular rash involving his trunk and limbs with some areas of confluence. There are oral mucosal erosions and bilateral conjunctival injection. Temperature is 38.9°C. The rash began 10 days after starting lamotrigine. What is the most appropriate immediate management?
A 14-year-old girl with type 1 diabetes for 5 years presents with bilateral pain and stiffness in her hands and feet, particularly in the mornings. On examination, she has bilateral flexion contractures at the metacarpophalangeal joints with waxy, tight skin over the dorsum of her hands. She is unable to approximate her palms together in a 'prayer sign'. Her HbA1c is 75 mmol/mol. What is the most likely diagnosis?
A 9-year-old girl with type 1 diabetes for 3 years uses insulin glargine 16 units at bedtime and insulin aspart before meals (carbohydrate ratio 1:10). Her blood glucose readings over the past week show: fasting 4-6 mmol/L, pre-lunch 10-14 mmol/L, pre-dinner 5-7 mmol/L, bedtime 6-9 mmol/L. She eats breakfast (40g carbohydrate) at 0730 and has a mid-morning snack at school (15g carbohydrate, no insulin) at 1030. What is the most appropriate adjustment to optimize her glycaemic control?
A 16-year-old boy with type 1 diabetes for 9 years attends clinic for transition planning to adult services. His current regimen includes insulin degludec once daily and insulin aspart before meals. His HbA1c has ranged between 58-64 mmol/mol over the past year. He reports occasional missed insulin doses when out with friends and has had two episodes of severe hypoglycaemia in the past 6 months requiring assistance. He plans to attend university next year. What aspect of his diabetes management represents the highest priority to address before transition?
A 6-year-old girl with childhood absence epilepsy has been on ethosuximide 250mg twice daily for 6 months with complete seizure control. Her parents report no adverse effects and she is doing well at school. Her EEG shows complete resolution of the 3 Hz spike-and-wave discharges that were present at diagnosis. Her parents ask about the long-term prognosis and treatment duration. What is the most appropriate advice regarding treatment continuation and prognosis?
A 4-year-old boy with type 1 diabetes is brought to the emergency department by ambulance. He was found unresponsive by his parents. Paramedics measured a blood glucose of 1.8 mmol/L and administered intramuscular glucagon 500 micrograms. On arrival, he is drowsy but responsive to voice, blood glucose is 3.2 mmol/L. He has vomited once. What is the most appropriate immediate management?
An 8-year-old boy with drug-resistant focal epilepsy is being evaluated for epilepsy surgery. Video-EEG telemetry has localized his seizure focus to the left anterior temporal lobe. MRI brain shows left mesial temporal sclerosis. Neuropsychological testing reveals age-appropriate cognitive function with right hemisphere language dominance. What is the most critical investigation that must be performed before proceeding with surgical resection?
A 13-year-old girl with type 1 diabetes for 7 years attends for her annual review. She uses a basal-bolus regimen with good adherence. Her HbA1c is 52 mmol/mol. Urinalysis shows albumin:creatinine ratio (ACR) of 3.8 mg/mmol on two occasions 3 months apart (early morning samples). Blood pressure is 118/72 mmHg (90th centile for age, gender, and height). Serum creatinine is normal. What is the most appropriate next management step?
A 10-year-old girl with absence epilepsy has been treated with ethosuximide 500mg daily for 8 months with good seizure control. She now presents with a 2-week history of lethargy, fever, mouth ulcers, and a non-blanching petechial rash on her legs. Blood tests reveal: Hb 68 g/L, WCC 1.8 × 10⁹/L (neutrophils 0.4 × 10⁹/L), platelets 42 × 10⁹/L. What is the most likely diagnosis and immediate management required?
A 7-year-old boy with newly diagnosed type 1 diabetes is being commenced on insulin therapy. His diabetes team explains the different types of insulin available. His regimen will include insulin aspart with meals and insulin detemir at bedtime. The parents ask how quickly the mealtime insulin starts to work. What is the typical onset of action for insulin aspart?
Chronic Paediatric Conditions UK Medical PG Practice Questions and MCQs
Question 11: A 6-year-old boy with epilepsy controlled on lamotrigine presents with a 2-day history of fever, malaise, and a widespread erythematous rash. On examination, he has a maculopapular rash involving his trunk and limbs with some areas of confluence. There are oral mucosal erosions and bilateral conjunctival injection. Temperature is 38.9°C. The rash began 10 days after starting lamotrigine. What is the most appropriate immediate management?
- A. Continue lamotrigine and treat symptomatically with antipyretics
- B. Reduce lamotrigine dose by 50% and review in 48 hours
- C. Stop lamotrigine immediately and admit for monitoring (Correct Answer)
- D. Add oral antihistamines and topical corticosteroids
- E. Change to carbamazepine and continue anti-epileptic treatment
Explanation: ***Stop lamotrigine immediately and admit for monitoring*** - The patient's presentation with **fever**, widespread **maculopapular rash** with confluence, **oral mucosal erosions**, and **conjunctival injection** strongly suggests a severe cutaneous adverse reaction like **Stevens-Johnson Syndrome (SJS)**. - **Lamotrigine** is a well-known culprit for SJS/TEN; immediate withdrawal of the offending drug is the most critical step to prevent progression and potential mortality, requiring inpatient monitoring. *Continue lamotrigine and treat symptomatically with antipyretics* - Continuing lamotrigine in the presence of features highly suggestive of **SJS** would be extremely dangerous, as the drug is the likely cause of the immune-mediated reaction. - Symptomatic treatment with antipyretics alone does not address the underlying **life-threatening drug hypersensitivity reaction** and risks rapid progression of the disease. *Reduce lamotrigine dose by 50% and review in 48 hours* - For a severe **idiosyncratic drug reaction** like SJS, simply reducing the dose is insufficient; even a reduced dose will continue to trigger the immune response. - Delaying definitive management (stopping the drug and admitting for aggressive supportive care) by 48 hours can lead to significant worsening of **skin detachment** and systemic complications. *Add oral antihistamines and topical corticosteroids* - Oral antihistamines and topical corticosteroids are treatments for **mild allergic rashes** or localized inflammatory conditions, not for a severe, systemic mucocutaneous reaction like SJS. - These interventions would be entirely inadequate for managing widespread **mucosal erosions** and systemic symptoms associated with SJS, failing to halt disease progression. *Change to carbamazepine and continue anti-epileptic treatment* - **Carbamazepine** is another aromatic anticonvulsant that carries a significant risk of causing **severe cutaneous adverse reactions**, including SJS/TEN, and has potential **cross-reactivity** with lamotrigine. - Switching to another high-risk drug during an acute, severe **hypersensitivity reaction** is contraindicated and could exacerbate the condition or trigger a similar reaction.
Question 12: A 14-year-old girl with type 1 diabetes for 5 years presents with bilateral pain and stiffness in her hands and feet, particularly in the mornings. On examination, she has bilateral flexion contractures at the metacarpophalangeal joints with waxy, tight skin over the dorsum of her hands. She is unable to approximate her palms together in a 'prayer sign'. Her HbA1c is 75 mmol/mol. What is the most likely diagnosis?
- A. Juvenile idiopathic arthritis
- B. Diabetic cheiroarthropathy (Correct Answer)
- C. Dupuytren's contracture
- D. Carpal tunnel syndrome
- E. Systemic sclerosis
Explanation: ***Diabetic cheiroarthropathy*** - This condition, also known as **limited joint mobility syndrome**, is characterized by bilateral flexion contractures at the metacarpophalangeal joints, waxy, tight skin, and the inability to approximate palms (the **'prayer sign'**). - It is strongly associated with long-standing **Type 1 Diabetes** and poor glycemic control, evidenced by the high HbA1c, due to **non-enzymatic glycosylation of collagen**. *Juvenile idiopathic arthritis* - Typically presents with visible **joint swelling**, warmth, and effusion, which are not described in this patient's presentation. - While it causes morning stiffness, it is not specifically associated with the **waxy skin changes** or the high HbA1c levels indicative of diabetic complications. *Dupuytren's contracture* - Involves the thickening and shortening of the **palmar fascia**, leading to permanent flexion of specific fingers, most commonly the ring and little fingers. - It presents with palpable **fascial nodules** or cords, not generalized waxy skin, bilateral symmetrical stiffness involving all digits, or the 'prayer sign'. *Carpal tunnel syndrome* - Primarily presents with **paresthesia**, numbness, and pain in the **median nerve** distribution, often worsening at night. - It does not cause the **'prayer sign'** or the widespread cutaneous thickening and stiffness of the small joints described in this case. *Systemic sclerosis* - While it can feature **sclerodactyly** and tight skin, it is usually accompanied by **Raynaud’s phenomenon**, digital ulcers, and systemic organ involvement. - The strong clinical association with poorly controlled diabetes (high **HbA1c**) and the specific 'prayer sign' points more directly to diabetic cheiroarthropathy.
Question 13: A 9-year-old girl with type 1 diabetes for 3 years uses insulin glargine 16 units at bedtime and insulin aspart before meals (carbohydrate ratio 1:10). Her blood glucose readings over the past week show: fasting 4-6 mmol/L, pre-lunch 10-14 mmol/L, pre-dinner 5-7 mmol/L, bedtime 6-9 mmol/L. She eats breakfast (40g carbohydrate) at 0730 and has a mid-morning snack at school (15g carbohydrate, no insulin) at 1030. What is the most appropriate adjustment to optimize her glycaemic control?
- A. Increase insulin glargine dose to 18 units at bedtime
- B. Increase breakfast insulin aspart by 1-2 units to cover the elevated pre-lunch readings (Correct Answer)
- C. Reduce breakfast insulin aspart by 1 unit as basal insulin is too high
- D. Administer rapid-acting insulin to cover the mid-morning snack
- E. Change insulin glargine from bedtime to morning administration
Explanation: ***Increase breakfast insulin aspart by 1-2 units to cover the elevated pre-lunch readings*** - The patient's **pre-lunch blood glucose** readings (10-14 mmol/L) are consistently elevated, indicating **insufficient insulin coverage** for the breakfast and mid-morning snack combined. Her **fasting glucose** is within target. - This specific post-breakfast hyperglycemia suggests the **breakfast bolus insulin (aspart)** is inadequate for the 40g breakfast and potentially the 15g mid-morning snack, making an adjustment to this dose the most direct and effective solution. *Increase insulin glargine dose to 18 units at bedtime* - The **fasting blood glucose** (4-6 mmol/L) is currently well-controlled, indicating that the **basal insulin (glargine)** dose is appropriate and not the cause of the pre-lunch hyperglycemia. - Increasing basal insulin without evidence of elevated fasting glucose could lead to **nocturnal hypoglycemia**. *Reduce breakfast insulin aspart by 1 unit as basal insulin is too high* - The current problem is **hyperglycemia** before lunch, suggesting *too little*, not too much, insulin for the morning carbohydrate intake. - Reducing the breakfast insulin aspart would further **worsen the elevated pre-lunch glucose** and is contrary to the observed pattern. *Administer rapid-acting insulin to cover the mid-morning snack* - While the 15g carbohydrate snack contributes to the pre-lunch rise, adding a separate insulin injection for such a small amount increases the **burden of treatment** and the risk of **insulin stacking** if not timed carefully with breakfast insulin. - A more practical and common approach is to adjust the **breakfast bolus** to cover the anticipated total morning carbohydrate load, including the snack. *Change insulin glargine from bedtime to morning administration* - The current bedtime administration of **insulin glargine** effectively controls overnight and **fasting glucose levels**, which are within target. - Changing the timing of basal insulin would not address the **post-breakfast insulin deficiency** and could potentially disrupt the currently stable fasting profile without benefit.
Question 14: A 16-year-old boy with type 1 diabetes for 9 years attends clinic for transition planning to adult services. His current regimen includes insulin degludec once daily and insulin aspart before meals. His HbA1c has ranged between 58-64 mmol/mol over the past year. He reports occasional missed insulin doses when out with friends and has had two episodes of severe hypoglycaemia in the past 6 months requiring assistance. He plans to attend university next year. What aspect of his diabetes management represents the highest priority to address before transition?
- A. His suboptimal HbA1c levels requiring treatment intensification with insulin pump therapy
- B. Recurrent severe hypoglycaemia requiring urgent review of insulin regimen and hypoglycaemia awareness (Correct Answer)
- C. Need for structured education on alcohol effects and diabetes management in social situations
- D. Inadequate preparation for independent self-management requiring more frequent clinic visits
- E. Lack of continuous glucose monitoring technology to improve glycaemic control
Explanation: ***Recurrent severe hypoglycaemia requiring urgent review of insulin regimen and hypoglycaemia awareness***- **Severe hypoglycaemia** (requiring assistance) is a life-threatening acute complication and represents the highest **clinical risk** during the transition to independent university life.- Addressing this requires an urgent assessment of **hypoglycaemia unawareness** and a review of basal insulin doses to ensure patient safety before he leaves home.*His suboptimal HbA1c levels requiring treatment intensification with insulin pump therapy*- While his **HbA1c** (7.5-8.0%) is above the target, intensifying therapy prematurely could increase the risk of further **severe hypoglycaemic episodes**.- Safety and **glycaemic stability** must be prioritised over achieving a lower HbA1c in a patient already experiencing frequent severe lows.*Need for structured education on alcohol effects and diabetes management in social situations*- Education on **alcohol-induced hypoglycaemia** is important for university students, but it is a subset of the broader clinical priority of managing his current **hypoglycaemia risk**.- This is a preventive education strategy rather than an urgent clinical intervention for a pre-existing pattern of **neuroglycopenia**.*Inadequate preparation for independent self-management requiring more frequent clinic visits*- Frequent clinic visits do not directly resolve the physiological danger of **severe hypoglycaemia** or the underlying technical issues with his insulin regimen.- The goal of transition is to foster **autonomy** and self-efficacy; simply increasing visit frequency may hinder the development of **self-management skills**.*Lack of continuous glucose monitoring technology to improve glycaemic control*- **Continuous glucose monitoring (CGM)** is a useful tool to detect trends, but technology alone cannot replace the necessary review of **insulin dosing** and hypoglycaemia awareness.- While CGM can alert a patient to drops, the immediate priority is understanding why **third-party assistance** was required twice in a short period.
Question 15: A 6-year-old girl with childhood absence epilepsy has been on ethosuximide 250mg twice daily for 6 months with complete seizure control. Her parents report no adverse effects and she is doing well at school. Her EEG shows complete resolution of the 3 Hz spike-and-wave discharges that were present at diagnosis. Her parents ask about the long-term prognosis and treatment duration. What is the most appropriate advice regarding treatment continuation and prognosis?
- A. Continue ethosuximide until age 12 then attempt withdrawal; 90% will remain seizure-free into adulthood
- B. Continue ethosuximide for minimum 2 years after last seizure; 60-70% will achieve long-term remission (Correct Answer)
- C. Attempt drug withdrawal now as EEG has normalized; relapse risk is less than 10% with normal EEG
- D. Continue ethosuximide lifelong as childhood absence epilepsy always requires ongoing treatment
- E. Switch to sodium valproate for better long-term seizure control as ethosuximide is only for initial treatment
Explanation: ***Continue ethosuximide for minimum 2 years after last seizure; 60-70% will achieve long-term remission***- Standard clinical guidelines suggest that **anti-epileptic drug (AED) withdrawal** should only be considered after a minimum of **2 years of complete seizure freedom**.- While **childhood absence epilepsy (CAE)** has an excellent prognosis, only about **60-70%** of patients achieve permanent remission, as some may transition to other seizure types like **Juvenile Myoclonic Epilepsy**.*Continue ethosuximide until age 12 then attempt withdrawal; 90% will remain seizure-free into adulthood*- Waiting until age 12 is an **arbitrary threshold**; the decision to taper is based on the duration of seizure freedom (usually 2 years) rather than a specific age.- A **90% success rate** for long-term remission is overly optimistic, as reaching adulthood seizure-free without medication occurs in roughly two-thirds of cases.*Attempt drug withdrawal now as EEG has normalized; relapse risk is less than 10% with normal EEG*- Withdrawing medication after only **6 months** is premature and carries a significantly **higher risk of relapse**, regardless of the current EEG findings.- A **normal EEG** is a positive prognostic marker, but it does not guarantee a relapse risk of less than 10% if the treatment duration was insufficient.*Continue ethosuximide lifelong as childhood absence epilepsy always requires ongoing treatment*- This is incorrect because CAE is one of the most likely epilepsy syndromes to exhibit **spontaneous resolution** during adolescence.- **Lifelong treatment** is generally reserved for syndromes like **Juvenile Myoclonic Epilepsy**, which typically require long-term AED therapy.*Switch to sodium valproate for better long-term seizure control as ethosuximide is only for initial treatment*- **Ethosuximide** is the first-line treatment for CAE and is sufficient for long-term management if it provides **complete seizure control** without side effects.- **Sodium valproate** is reserved for cases where ethosuximide fails or if the patient experiences associated **generalized tonic-clonic seizures**.
Question 16: A 4-year-old boy with type 1 diabetes is brought to the emergency department by ambulance. He was found unresponsive by his parents. Paramedics measured a blood glucose of 1.8 mmol/L and administered intramuscular glucagon 500 micrograms. On arrival, he is drowsy but responsive to voice, blood glucose is 3.2 mmol/L. He has vomited once. What is the most appropriate immediate management?
- A. Administer intravenous 10% glucose bolus at 5 mL/kg followed by maintenance infusion (Correct Answer)
- B. Commence intravenous 0.9% sodium chloride bolus 10 mL/kg over 30 minutes
- C. Administer a second dose of intramuscular glucagon and recheck glucose in 10 minutes
- D. Give oral glucose gel 1.5-2g per kg and monitor capillary glucose every 15 minutes
- E. Give oral quick-acting carbohydrate (e.g., juice) once fully conscious then long-acting carbohydrate
Explanation: ***Administer intravenous 10% glucose bolus at 5 mL/kg followed by maintenance infusion***- In a child with **hypoglycemia** who is **drowsy** and has **vomited**, oral or enteral treatments are unsafe due to the high risk of **aspiration**.- Since **glucagon** works by mobilizing **glycogen stores**, its effect is transient; providing a **10% glucose bolus** followed by an infusion ensures stabilization and prevents rebound hypoglycemia.*Commence intravenous 0.9% sodium chloride bolus 10 mL/kg over 30 minutes*- This intervention is used for **circulatory collapse** or **dehydration**, but it does not contain **glucose** to correct the primary metabolic emergency.- Administering saline without glucose in this context would delay the correction of **neuroglycopenia**.*Administer a second dose of intramuscular glucagon and recheck glucose in 10 minutes*- **Glucagon** is often ineffective for repeated doses because the initial dose likely **depleted hepatic glycogen stores**.- Glucagon frequently induces **vomiting**, making continued reliance on it problematic when intravenous access is available to provide a more reliable glucose source.*Give oral glucose gel 1.5-2g per kg and monitor capillary glucose every 15 minutes*- Oral glucose gel is contraindicated in patients with an **altered level of consciousness** as they cannot protect their airway.- This patient has already **vomited**, indicating that the **gastrointestinal route** is currently unreliable and potentially hazardous.*Give oral quick-acting carbohydrate (e.g., juice) once fully conscious then long-acting carbohydrate*- While this is the protocol for **mild to moderate hypoglycemia**, this patient's current state is **severe** and necessitates faster, parenteral intervention.- Waiting for the patient to become "fully conscious" without active IV correction delays treatment for a child who is currently **symptomatically hypoglycemic** (3.2 mmol/L with drowsiness).
Question 17: An 8-year-old boy with drug-resistant focal epilepsy is being evaluated for epilepsy surgery. Video-EEG telemetry has localized his seizure focus to the left anterior temporal lobe. MRI brain shows left mesial temporal sclerosis. Neuropsychological testing reveals age-appropriate cognitive function with right hemisphere language dominance. What is the most critical investigation that must be performed before proceeding with surgical resection?
- A. Functional MRI to map eloquent cortex and determine language lateralization (Correct Answer)
- B. Intracranial EEG monitoring with subdural electrodes to refine seizure focus
- C. Wada test (intracarotid sodium amobarbital procedure) to assess memory function
- D. Repeat MRI with magnetoencephalography to confirm seizure localization
- E. PET scan to identify areas of hypometabolism
Explanation: ***Functional MRI to map eloquent cortex and determine language lateralization*** - **Functional MRI (fMRI)** is crucial for **pre-surgical planning** to non-invasively map **eloquent cortex** and determine **language lateralization**, especially when the seizure focus is near critical functional areas. - Given the patient's **right hemisphere language dominance** and the seizure focus in the **left anterior temporal lobe**, fMRI is essential to precisely identify and spare language areas during resection, preventing significant postoperative deficits. *Intracranial EEG monitoring with subdural electrodes to refine seizure focus* - This is an **invasive procedure** generally considered when non-invasive studies (video-EEG, MRI) are **discordant** or insufficient for precise localization, or when the seizure focus is intimately associated with eloquent cortex. - In this case, the **video-EEG** and **MRI** findings are already **concordant** for left mesial temporal sclerosis, making functional mapping more immediately critical than further invasive localization. *Wada test (intracarotid sodium amobarbital procedure) to assess memory function* - The **Wada test** is an **invasive procedure** with associated risks, traditionally used for **language and memory lateralization** prior to epilepsy surgery. - For pediatric patients, it has largely been superseded by **non-invasive fMRI**, which provides safer and often more detailed functional mapping of language and memory regions. *Repeat MRI with magnetoencephalography to confirm seizure localization* - **Magnetoencephalography (MEG)** is valuable for localizing seizure activity, particularly in cases of **non-lesional epilepsy** or when the EEG is inconclusive. - However, this patient already has a clear structural lesion (**left mesial temporal sclerosis**) and **concordant video-EEG** localization, making further localization less critical than functional mapping for surgical safety. *PET scan to identify areas of hypometabolism* - A **PET scan (FDG-PET)** can identify areas of **interictal hypometabolism** that often correlate with the seizure onset zone, providing supportive evidence for localization. - While useful for supporting seizure focus localization, a PET scan does not provide the critical **functional mapping** information needed to protect eloquent brain regions during surgical resection.
Question 18: A 13-year-old girl with type 1 diabetes for 7 years attends for her annual review. She uses a basal-bolus regimen with good adherence. Her HbA1c is 52 mmol/mol. Urinalysis shows albumin:creatinine ratio (ACR) of 3.8 mg/mmol on two occasions 3 months apart (early morning samples). Blood pressure is 118/72 mmHg (90th centile for age, gender, and height). Serum creatinine is normal. What is the most appropriate next management step?
- A. Reassure that results are within normal limits and continue annual screening
- B. Arrange renal ultrasound to exclude structural abnormalities
- C. Increase frequency of ACR monitoring to every 3 months and optimize glycaemic control (Correct Answer)
- D. Refer to paediatric nephrology for renal biopsy
- E. Commence ACE inhibitor therapy to prevent progression of diabetic nephropathy
Explanation: ***Increase frequency of ACR monitoring to every 3 months and optimize glycaemic control*** - The patient has **persistent microalbuminuria** (ACR 3.8 mg/mmol on two occasions), which is above the normal threshold and indicates the earliest stage of **diabetic nephropathy**. - In pediatric patients, the initial management focus for early diabetic nephropathy is to **intensify monitoring** of ACR and to optimize modifiable risk factors, particularly **glycaemic control** (HbA1c 52 mmol/mol, still with room for improvement) and blood pressure. *Reassure that results are within normal limits and continue annual screening* - An ACR of 3.8 mg/mmol is **abnormally elevated** and signifies early renal damage, therefore, it cannot be considered within normal limits. - Continuing only **annual screening** is insufficient when early signs of kidney involvement are present; more frequent assessment and intervention are warranted. *Arrange renal ultrasound to exclude structural abnormalities* - **Diabetic nephropathy** is a functional complication primarily affecting the microvasculature, and a **renal ultrasound** is not a standard investigation for isolated microalbuminuria in Type 1 Diabetes. - Structural abnormalities are usually investigated only if there are atypical features like **macroscopic hematuria**, rapidly declining **GFR**, or signs of urinary tract obstruction. *Refer to paediatric nephrology for renal biopsy* - A **renal biopsy** is an invasive procedure that is not warranted for the typical presentation of **early diabetic kidney disease** with normal serum creatinine and isolated microalbuminuria. - It is generally reserved for cases where the diagnosis is in doubt or there is suspicion of a **non-diabetic glomerulopathy**. *Commence ACE inhibitor therapy to prevent progression of diabetic nephropathy* - **ACE inhibitors** are typically considered for children with persistent microalbuminuria who also have **hypertension** (blood pressure >95th centile) or progressive albuminuria despite optimization of other risk factors. - This patient's blood pressure (90th centile) is not yet classified as hypertension, making the initiation of pharmacological therapy like ACE inhibitors premature as the initial step.
Question 19: A 10-year-old girl with absence epilepsy has been treated with ethosuximide 500mg daily for 8 months with good seizure control. She now presents with a 2-week history of lethargy, fever, mouth ulcers, and a non-blanching petechial rash on her legs. Blood tests reveal: Hb 68 g/L, WCC 1.8 × 10⁹/L (neutrophils 0.4 × 10⁹/L), platelets 42 × 10⁹/L. What is the most likely diagnosis and immediate management required?
- A. Aplastic anaemia secondary to ethosuximide; stop drug immediately and arrange urgent haematology referral (Correct Answer)
- B. Immune thrombocytopenic purpura; commence prednisolone and continue ethosuximide
- C. Acute lymphoblastic leukaemia; stop ethosuximide and arrange urgent oncology assessment
- D. Viral-induced bone marrow suppression; provide supportive care and continue ethosuximide
- E. Ethosuximide toxicity; reduce dose by 50% and monitor blood counts weekly
Explanation: ***Aplastic anaemia secondary to ethosuximide; stop drug immediately and arrange urgent haematology referral***- The patient presents with **pancytopenia** (low Hb, WCC, and platelets), which is a rare but life-threatening idiosyncratic reaction to **ethosuximide**.- Clinical features like **lethargy** (anemia), **fever/mouth ulcers** (neutropenia), and **petechiae** (thrombocytopenia) necessitate immediate drug cessation and a **bone marrow examination**.*Immune thrombocytopenic purpura; commence prednisolone and continue ethosuximide*- **Immune thrombocytopenic purpura (ITP)** typically presents with isolated thrombocytopenia, not the **pancytopenia** seen in this patient's blood results.- Prednisolone is used for ITP, but it would not address the **bone marrow failure** caused by drug-induced suppression.*Acute lymphoblastic leukaemia; stop ethosuximide and arrange urgent oncology assessment*- While **Acute lymphoblastic leukaemia (ALL)** can cause pancytopenia and fever, the temporal relationship with **ethosuximide** makes drug-induced aplastic anemia more likely.- ALL often presents with **lymphadenopathy** or **hepatosplenomegaly**, which are not reported in this clinical scenario.*Viral-induced bone marrow suppression; provide supportive care and continue ethosuximide*- Although **viral infections** (like Parvovirus B19) can cause marrow suppression, the risk of continuing a potentially causative drug like **ethosuximide** in the face of severe pancytopenia is too high.- Supportive care alone is insufficient; the offending agent must be **discontinued** to allow for marrow recovery.*Ethosuximide toxicity; reduce dose by 50% and monitor blood counts weekly*- **Idiosyncratic reactions** like aplastic anemia are not dose-dependent; therefore, reducing the dose is inadequate and dangerous.- Severe **neutropenia** (0.4 x 10⁹/L) and thrombocytopenia represent a medical emergency that cannot be managed by simple monitoring.
Question 20: A 7-year-old boy with newly diagnosed type 1 diabetes is being commenced on insulin therapy. His diabetes team explains the different types of insulin available. His regimen will include insulin aspart with meals and insulin detemir at bedtime. The parents ask how quickly the mealtime insulin starts to work. What is the typical onset of action for insulin aspart?
- A. 1-2 minutes
- B. 30-60 minutes
- C. 6-8 hours
- D. 10-20 minutes (Correct Answer)
- E. 2-4 hours
Explanation: ***10-20 minutes*** - **Insulin aspart** is a **rapid-acting insulin analogue** specifically engineered for quick absorption, with its typical onset of action occurring within **10 to 20 minutes** after subcutaneous injection. - This rapid onset allows it to cover the immediate rise in blood glucose following meals, making it ideal for **mealtime insulin** administration right before or shortly after eating. *1-2 minutes* - This onset timeframe is extremely short and does not align with the **pharmacokinetics** of any currently available subcutaneous insulin, as absorption takes longer. - Even for intravenous insulin, the metabolic effect takes longer to fully manifest compared to this duration. *30-60 minutes* - This duration is characteristic of the onset of **Regular (Soluble) human insulin**, which is a **short-acting insulin**, not a rapid-acting analogue. - Regular insulin requires administration 30-45 minutes before a meal to adequately cover post-prandial glucose excursions, which differs from rapid-acting insulins. *6-8 hours* - This timeframe is typically associated with the **duration of action** for intermediate-acting insulins (like NPH) or the **peak effect** of some longer-acting insulins. - It is far too long for the **onset of action** of any insulin, especially a mealtime insulin, which needs to act quickly. *2-4 hours* - This is the approximate onset of action for **long-acting basal insulins** such as **insulin detemir** (as mentioned in the patient's regimen) or **insulin glargine**. - These insulins provide a sustained background insulin level and are not designed for rapid control of glucose spikes associated with meals.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free